| Id: | acc2525 |
| Group: | 2sens |
| Protein: | AMPK |
| Gene Symbol: | PRKAA2 |
| Protein Id: | P54646 |
| Protein Name: | AAPK2_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr172 |
| Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | HepG2 |
| Disease Info: | |
| Drug: | berberine(BBR) |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | "BBR inhibits lipid synthesis in HepG2 liver cancer cells by phosphorylating AMPK, which may reduce the fatty acids required for cellular energy supply and growth, thereby inhibiting the proliferation of liver cancer cells." |
| Note: | no tumor effct |
| Score: | 3.0 |
| Pubmed(PMID): | 16508037 |
| Sentence Index: | 16508037_2-3 |
| Sentence: | "Using HepG2 human hepatoma cells, we found that BBR inhibits cholesterol and TG synthesis in a similar manner to the AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR). Significant increases in AMPK phosphorylation and AMPK activity were observed when the cells were incubated with BBR." |
Sequence & Structure:
MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGKIKREIQNLKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEMEARRLFQQILSAVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSCGVILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPEYLNRSVATLLMHMLQVDPLKRATIKDIREHEWFKQDLPSYLFPEDPSYDANVIDDEAVKEVCEKFECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQASEFYLASSPPSGSFMDDSAMHIPPGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWHLGIRSQSKPYDIMAEVYRAMKQLDFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDNRSYLLDFKSIDDEVVEQRSGSSTPQRSCSAAGLHRPRSSFDSTTAESHSLSGSLTGSLTGSTLSSVSPRLGSHTMDFFEMCASLITTLAR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PRKAA2 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
| PRKAA2 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| PRKAA2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.934 |
| HGSC | -1.055 |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | 0.121 |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
